[Form 4] ZyVersa Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Equitable Holdings, Inc. (EQH) filed a Form 144 disclosing a proposed insider sale under Rule 144.

• Seller & broker: Mark Pearson (per past-sale table) intends to sell 30,000 common shares through Morgan Stanley Smith Barney LLC.
• Market value: At the reference price, the shares are valued at $1,602,300.
• Sale timing & venue: Target date 07/15/2025; shares to be sold on the NYSE.
• Outstanding shares: 303,895,221; the proposed sale equals roughly 0.01 % of shares outstanding.
• Prior activity: The same account executed four 10b5-1 sales over the last three months, totaling 60,000 shares for gross proceeds of ≈ $3.18 million.
• Source of shares: 20,000 shares were acquired via option exercise on 07/15/2025; 10,000 via RSUs on 02/14/2022.

No additional financial metrics, earnings data, or business updates were provided; the filing is limited to disclosure of planned insider transactions.

Insights

Insider Transactions Analyst

TL;DR: Routine-size insider sale (0.01 % float); modest negative sentiment, immaterial fundamental impact.

The Form 144 reveals a forthcoming 30 k-share sale worth ~$1.6 M, following 60 k shares already sold in the prior quarter. While serial selling can raise eyebrows, the cumulative 90 k shares represent just 0.03 % of EQH’s 303.9 M shares outstanding, limiting dilution or supply risk. Use of a 10b5-1 plan and transparent Rule 144 notice suggest pre-planned diversification rather than reactive selling. Absent any new adverse operational data, I view the filing as neutral to slightly negative: it may pressure sentiment but is unlikely to shift valuation multiples.

Portfolio Manager

TL;DR: Insider cashes out $1.6 M; scale too small to alter portfolio stance.

From an allocation viewpoint, a 30 k-share dump on a >300 M-share base is noise. Liquidity on NYSE should absorb it without affecting spreads. Nonetheless, repeated insider selling can weigh on perception of forward prospects, especially lacking offsetting insider buys. Investors may monitor if additional Form 144s surface. I assign minimal fundamental impact but note a marginal uptick in sentiment risk.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Guzman Pablo A.

(Last) (First) (Middle)

C/O ZYVERSA THERAPEUTICS, INC.

2200 N. COMMERCE PARKWAY, SUITE 208

(Street)

WESTON FL 26333

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZyVersa Therapeutics, Inc. [ ZVSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.59	07/11/2025		A		48,900		(1)	07/11/2035	Common Stock	48,900	$0	48,900	D

Explanation of Responses:

1. The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

	s/ Stephen C. Glover as Attorney-in-Fact for Pablo Guzman pursuant to Power of Attorney	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Equitable Holdings (EQH) shares are proposed for sale in the Form 144?

The filing covers 30,000 common shares.

What is the estimated market value of the EQH shares to be sold?

The aggregate market value is $1,602,300.

When is the planned sale date for the EQH Form 144 transaction?

The approximate sale date disclosed is 07/15/2025.

What percentage of EQH’s outstanding shares does this sale represent?

About 0.01 % of the 303,895,221 shares outstanding.

How many shares has the filer sold in the past three months?

Past 10b5-1 sales total 60,000 shares with gross proceeds of roughly $3.18 million.

Which broker will handle the proposed EQH share sale?

Morgan Stanley Smith Barney LLC, Executive Financial Services division.